OPKO Health Files 8-K Report

TL;DR

OPKO Health filed an 8-K, likely with financial updates and other disclosures.

AI Summary

On September 15, 2025, OPKO Health, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or new material events were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates that OPKO Health, Inc. is providing updated information to the SEC, which could include material disclosures relevant to investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report, and the provided excerpt does not contain information indicating significant new risks.

Key Players & Entities

• OPKO Health, Inc. (company) — Registrant
• September 15, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 001-33528 (filing_id) — Commission File Number
• 75-2402409 (tax_id) — IRS Employer Identification No.
• 4400 Biscayne Blvd. (address) — Principal Executive Offices
• Miami (location) — City of Principal Executive Offices
• Florida (location) — State of Principal Executive Offices
• 33137 (zip_code) — Zip Code of Principal Executive Offices

FAQ

Key Financial Figures

• $225,000,000 — or an aggregate purchase price of up to $225,000,000 in cash (the " Transaction "), of which
• $192,500,000 — in cash (the " Transaction "), of which $192,500,000 is payable by Buyer in cash upon closin
• $32,500,000 — n closing of the Transaction, and up to $32,500,000 of contingent consideration is payable

Filing Documents

• opk-20250915.htm (8-K) — 53KB
• opk-ex99_1.htm (EX-99.1) — 22KB
• 0001193125-25-203530.txt ( ) — 181KB
• opk-20250915.xsd (EX-101.SCH) — 23KB
• opk-20250915_htm.xml (XML) — 4KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 15, 2025, OPKO Health, Inc., a Delaware corporation (" OPKO "), issued a press release announcing the completion of the Transaction (as defined in Item 8.01 of this Current Report on Form 8-K). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference in this Item 7.01. The information contained in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (" Exchange Act "), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act except to the extent expressly stated in such filing.

01 Other Events

Item 8.01 Other Events. As previously reported, on March 10, 2025, OPKO, its wholly owned subsidiary, BioReference Health, LLC (" BioReference " and, together with OPKO, " Seller "), and Laboratory Corporation of America Holdings, a Delaware corporation (" Buyer "), entered into an Asset Purchase Agreement (the " Purchase Agreement "), pursuant to which Seller agreed to sell and assign to Buyer, and Buyer agreed to purchase and assume from Seller, certain assets and liabilities of BioReference's laboratory testing businesses focused on oncology and oncology-related clinical testing services across the United States, in exchange for an aggregate purchase price of up to $225,000,000 in cash (the " Transaction "), of which $192,500,000 is payable by Buyer in cash upon closing of the Transaction, and up to $32,500,000 of contingent consideration is payable in cash in accordance with the terms of a post-closing earnout based upon revenue generated by certain customer accounts. On September 15, 2025, the parties to the Purchase Agreement consummated the Transaction, and Buyer paid to Seller $192,500,000 in cash, subject to certain adjustments as set forth in the Purchase Agreement.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of the Company dated September 15, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OPKO Health, Inc. By: /s/ Adam Logal Date: September 15, 2025 Name: Adam Logal Title: Senior Vice President, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR